AstraZeneca to bolster US footprint with multi-billion dollar strategy
In a bold move set to reshape the pharmaceutical landscape, AstraZeneca has announced a substantial $3.5 billion investment aimed at expanding its research and manufacturing ... Read More
AstraZeneca achieves remarkable financial growth in 2023, fueling optimism for future innovations
AstraZeneca PLC unveiled its financial results for the fiscal year and fourth quarter of 2023 on 8 February 2024, marking a year of robust growth ... Read More
AstraZeneca launches Evinova to optimize clinical trials and patient care
AstraZeneca has announced the launch of Evinova, poised to become a leading provider in the digital health solutions domain. Backed by AstraZeneca and collaborating with ... Read More
AstraZeneca reports steady growth in 9M and Q3 2023 with core EPS increase
AstraZeneca has announced its financial results for the nine months (9M) and third quarter (Q3) of 2023, displaying solid financial performance with a focus on ... Read More
AstraZeneca to establish $360m API manufacturing facility in Ireland
AstraZeneca said that it will invest $360 million in Ireland for setting up an active pharmaceutical ingredient (API) manufacturing facility for small molecules near Dublin. ... Read More
AstraZeneca shareholders approve $39bn acquisition of Alexion
AstraZeneca has secured its shareholders’ approval for its previously announced $39 billion acquisition of US biopharma company Alexion Pharmaceuticals. The pharma giant expects the acquisition ... Read More
Covid antibody candidate AZD7442 : AstraZeneca, US strike deal for additional doses
AstraZeneca has agreed to supply the US government with up to half a million additional doses of AZD7442, the company’s Covid-19 antibody candidate, for a ... Read More
AstraZeneca signs $39bn deal to acquire Alexion Pharmaceuticals
In a landmark move that’s poised to shake up the world of immunology and rare disease treatments, AstraZeneca has sealed a $39 billion deal to ... Read More
AstraZeneca resumes AZD1222 Covid-19 vaccine trials after brief pause
AstraZeneca said that clinical trials for the AZD1222 Covid-19 vaccine candidate, have resumed in various parts of the world after regulators across the US, UK, ... Read More
AstraZeneca to advance AZD7442 into phase 3 Covid-19 trials
AstraZeneca said that AZD7442, which is being developed for the prevention and treatment of Covid-19, will move into two phase 3 clinical trials. AZD7442 is ... Read More